Goldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65

Deep News07-21

Investment bank Goldman Sachs has issued a research report, stating that JD HEALTH's (06618) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.

Goldman Sachs currently forecasts that JD HEALTH's adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its "Buy" rating on the stock, with a target price set at HK$65.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1144611319?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 23:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1144611319","market":"sh","top_or_hot":-1,"title":"Goldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65","media":"Deep News","content":"<p>Investment bank Goldman Sachs has issued a research report, stating that <b>JD HEALTH</b>'s (<b>06618</b>) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.<br><br>Goldman Sachs currently forecasts that <b>JD HEALTH</b>'s adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its \"Buy\" rating on the stock, with a target price set at HK$65.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs Affirms Buy Rating for JD Health, Sets Price Target at HK$65\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-21 23:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Investment bank Goldman Sachs has issued a research report, stating that <b>JD HEALTH</b>'s (<b>06618</b>) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.<br><br>Goldman Sachs currently forecasts that <b>JD HEALTH</b>'s adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its \"Buy\" rating on the stock, with a target price set at HK$65.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0456827905.SGD","symbol_name":"JPMorgan Funds - China A (acc) SGD","start_time":0,"source_url":"","article_id":"1144611319","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1144611319","pubTimestamp":1784646085,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Investment bank Goldman Sachs has issued a research report, stating that JD HEALTH's (06618) second-quarter revenue growth is anticipated to broadly align with market expectations. While the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","BK1571":"互联网医疗","BK1583":"高瓴概念","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK1247":"药品零售","06618":"京东健康","BK1589":"北水核心资产","BK1515":"抗疫概念","EWH":"香港ETF-iShares MSCI","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","LU0051755006.USD":"摩根大通中国A (dist)","BK1142":"互联网与直销零售","BK1591":"就地过年概念","BK1615":"港股-互联网"},"translate_title":"高盛确认京东健康买入评级，目标价65港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":1,"06618":1,"EWH":1},"content_text":"Investment bank Goldman Sachs has issued a research report, stating that JD HEALTH's (06618) second-quarter revenue growth is anticipated to broadly align with market expectations. While the performance of the 618 shopping festival was relatively subdued, driven by sustained market share gains in its core product categories, the current forecast projects a year-on-year revenue increase of 18% for the second quarter.Goldman Sachs currently forecasts that JD HEALTH's adjusted operating profit margin for the second quarter will be 7.1%, indicating continued improvement compared to the same period last year. The firm also anticipates an acceleration in the company's growth during the second half of the year. Consequently, Goldman Sachs has maintained its \"Buy\" rating on the stock, with a target price set at HK$65.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1144611319","isCrawlerRequest":true}